Aerami Therapeutics

For biopharmaceutical companies looking to go public, merging with a special purpose acquisition company can be an appealing alternative to the ‘traditional’ initial public offering process. Rather th

The biopharmaceutical industry is nearing the one-month mark without an initial public offering in the US as biotechnology stock values continue to plummet, mirroring the slowdown across industries as

Public biopharmaceutical company valuations have taken a sharp turn into the red in the US during the past month, plunging the industry’s market for initial public offering into a drought. This trend

The biopharmaceutical industry set a new record in venture capital financing raised in a single year, with one quarter left to go in 2021. Drug developers raised $28bn in VC funding through the third